D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole

Drug Development and Industrial Pharmacy

Volumn 34, Issue 7, 2008, Pages 668-675

  Nahata, Tushar ^a   Saini, Tulsi Ram ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Aripiprazole; Cholesterol; D optimal design; Microsphere; Optimization; PLGA

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; MICROSPHERE; POLYGLACTIN; PURASORB; RESOMER;

ARTICLE; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; EVAPORATION; PARTICLE SIZE;

ANTIPSYCHOTIC AGENTS; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; LACTIC ACID; MICROSPHERES; PARTICLE SIZE; PIPERAZINES; POLYGLYCOLIC ACID; POLYMERS; QUINOLONES; SCHIZOPHRENIA; SOLUBILITY; SOLVENTS;

EID: 46949094157     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701836545     Document Type: Article

References (12)

1. Anderson, M., & Shive, M. S. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev., 28, 5-24.
2. Bhanji, N. H., & Margolese, H. C. (2004). A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol., 14, 87-92.
3. David, A. S. & Adams, C. (2001). Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes. Health Technol. Assess., 5, 34.
4. El-Malah, Y., Nazzal, S., & Khanfar, N. M. (2006). D-optimal mixture design: Optimization of ternary matrix blends for controlled zero order drug release from oral dosage forms. Drug Dev. Ind. Pharm., 32,1207-1218.
5. Gerlach, J. (1994). Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr. Scand. Suppl., 382, 28-32.
6. Grunder, G., Kungel, M., Ebrecht, M., Gorocs, T., & Modell, S. (2006). Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry, 39(1), S21-S25.
7. Harrison, T. S., & Perry, C. M. (2004). Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs, 64, 1715-1736.
8. Mura, P., Furlanetto, S., Cirri, M., Maestrelli, F., Marras, A. M., & Pinzauti, S. (2005). Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. J. Pharm. Biomed. Res., 37, 65-71.
9. Parikh, R. H., Parikh, J. R., Dubey, R. R., Soni, H. N., & Kapadia, K. N. (2003). Poly (D, L Lactide-co-Glycolide) microspheres containing 5 fluorouracil: Optimization of process parameters. AAPS PharmasciTech, 4, 1-7.
10. Sinha, V. R., & Trehan, A. (2005). Biodegradable micropsheres for parenteral delivery. Crit. Rev. Ther. Drug Crrier. Syst., 22, 535-602.
11. Uchida, T., Yoshida, K., Ninomiya, A., & Goto, S. (1995). Optimization of preparative conditions for PLA microspheres containing ovalbumin. Chem. Pharm. Bull., 43, 1569-1573.
12. Wang, L., Kleiner, L., & Venkatraman, S. (2003). Future formation in injectable poly (lactide-co-glycolide) depots. J. Control. Release, 90, 345-354.